Definium Therapeutics, Inc. (NASDAQ:DFTX) Given Average Rating of “Buy” by Analysts

Definium Therapeutics, Inc. (NASDAQ:DFTX) has been given an average recommendation of “Buy” by the seventeen brokerages that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a buy rating and two have given a strong buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $49.2308.

Several brokerages have recently issued reports on DFTX. Robert W. Baird raised their target price on shares of Definium Therapeutics from $37.00 to $57.00 and gave the stock an “outperform” rating in a report on Tuesday, June 23rd. Piper Sandler reiterated an “overweight” rating and set a $48.00 price target (down from $49.00) on shares of Definium Therapeutics in a report on Friday, May 8th. Leerink Partners set a $52.00 price target on shares of Definium Therapeutics and gave the company an “outperform” rating in a research report on Monday, June 22nd. Canaccord Genuity Group set a $58.00 price target on shares of Definium Therapeutics and gave the company a “buy” rating in a research report on Tuesday, June 30th. Finally, Needham & Company LLC raised their price target on shares of Definium Therapeutics from $38.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, June 23rd.

Insiders Place Their Bets

In other Definium Therapeutics news, insider Matthew T. Wiley sold 2,867 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $129,101.01. Following the completion of the transaction, the insider owned 174,633 shares of the company’s stock, valued at $7,863,723.99. This represents a 1.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Robert Barrow sold 29,208 shares of the stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $1,315,236.24. Following the completion of the sale, the chief executive officer owned 1,098,246 shares of the company’s stock, valued at approximately $49,454,017.38. This trade represents a 2.59% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 48,096 shares of company stock valued at $2,165,763 over the last three months. Company insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Definium Therapeutics

Hedge funds have recently made changes to their positions in the business. Royal Bank of Canada raised its holdings in shares of Definium Therapeutics by 10.4% during the first quarter. Royal Bank of Canada now owns 65,237 shares of the company’s stock valued at $382,000 after acquiring an additional 6,148 shares in the last quarter. Creative Planning boosted its holdings in Definium Therapeutics by 2.6% in the second quarter. Creative Planning now owns 66,097 shares of the company’s stock valued at $429,000 after acquiring an additional 1,655 shares in the last quarter. JPMorgan Chase & Co. increased its position in Definium Therapeutics by 5.1% during the 2nd quarter. JPMorgan Chase & Co. now owns 48,487 shares of the company’s stock valued at $315,000 after purchasing an additional 2,342 shares during the period. Rhumbline Advisers increased its position in Definium Therapeutics by 6.3% during the 2nd quarter. Rhumbline Advisers now owns 115,296 shares of the company’s stock valued at $748,000 after purchasing an additional 6,839 shares during the period. Finally, Russell Investments Group Ltd. raised its holdings in Definium Therapeutics by 110.4% in the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after purchasing an additional 2,003 shares in the last quarter. 27.91% of the stock is owned by hedge funds and other institutional investors.

Definium Therapeutics Price Performance

DFTX opened at $43.65 on Tuesday. The company has a debt-to-equity ratio of 0.15, a current ratio of 4.69 and a quick ratio of 4.69. The stock’s 50 day simple moving average is $29.65 and its 200 day simple moving average is $21.94. The firm has a market cap of $4.35 billion, a price-to-earnings ratio of -17.53 and a beta of 2.20. Definium Therapeutics has a 1 year low of $7.96 and a 1 year high of $49.20.

Definium Therapeutics (NASDAQ:DFTX) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.23). As a group, analysts predict that Definium Therapeutics will post -2.27 earnings per share for the current year.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.